MEMO: Does Muscle Mass at Intensive Care Unit Admission Determine Mortality: The Memo Study

Sponsor
University Hospital, Geneva (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05834894
Collaborator
VBertoniMaluf (Other)
4,000
1
169
23.7

Study Details

Study Description

Brief Summary

This retrospective monocentric study aims to investigate whether a low muscle mass at ICU admission and its loss over the ICU stay predicts mortality, and in what proportion we can counteract it by nutritional support.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The study hypothesis is that a low muscle mass at ICU admission, measured at the level of L3 on CT scans performed for clinical routine, and its change over the ICU stay predict the prognosis of the patient, especially the 30-day mortality, that it may at least be partly counteracted by nutritional support and that it is related with higher ICU and hospital costs.

    The objectives of this retrospective study are to determine:
    1. the link between baseline body composition at ICU admission and outcomes, such as 30-day, ICU and hospital mortality and LOS, and infections. If this is confirmed, we aim to evaluate the added values of body composition to ICU severity scores to predict 30-day mortality

    2. the link between baseline body composition vs. other locations to predict outcomes

    3. the impact of body composition changes on the afore-mentioned outcomes. If this is confirmed, we aim to evaluate the added value of changes in body composition to changes in ICU severity scores to predict 30-day mortality

    4. the impact of nutritional support on body composition changes

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    4000 participants
    Observational Model:
    Other
    Time Perspective:
    Retrospective
    Official Title:
    Does Muscle Mass at Intensive Care Unit Admission Determine Mortality: The Memo Study
    Actual Study Start Date :
    Jan 1, 2010
    Actual Primary Completion Date :
    Dec 31, 2022
    Anticipated Study Completion Date :
    Jan 31, 2024

    Outcome Measures

    Primary Outcome Measures

    1. 30-day mortality [30-day mortality between January 1st 2010 and December 31st 2022.]

      Association between skeletal muscle index (SMI) at the L3 vertebra level (psoas + abdominal wall muscles + paraspinal muscles), measured from 48 hours before to 96 hours after ICU admission, with 30-day mortality.

    Secondary Outcome Measures

    1. Association of baseline body composition at ICU admission with other outcomes [30-day]

      Association of Skeletal muscle area (SMA), SMAH (Skeletal muscle area/height), SMD (Skeletal muscle density), IMAT (intermuscular and intramuscular adipose tissue), visceral and subcutaneous adipose tissue at the L3 vertebra level with 30-day mortality Determination of cut-off points of SMI, by sex, below which there is an increased risk of 30-day mortality Added value of body composition to ICU severity scores to predict 30-day mortality Association of baseline SMI, SMA, SMAH, SMD, intermuscular, visceral and subcutaneous adipose tissue at the L3 level, with ICU and hospital mortality and LOS, 30-day ICU readmission, duration of mechanical ventilation and infections

    2. Association of baseline SMI at the L3 vertebra level vs. other locations to predict outcomes [Day 1 to day 30]

      Associations of SMI at the L3 vertebra level with SMI at the other locations Associations of SMI at the other locations with ICU and hospital mortality and LOS, 30-day ICU readmission, duration of mechanical ventilation and infections Comparison of the associations between muscle mass measured at the different anatomical locations and mortality in order to determine the best prognostic location

    3. Association of body composition changes with outcomes [Day 30]

      Association of changes in SMI, SMA, SMAH, SMD, IMAT, visceral and subcutaneous adipose tissue with 30-day mortality, ICU and hospital mortality and LOS, 30-day ICU readmission, duration of mechanical ventilation and infections Added value of changes in body composition to changes in ICU severity scores to predict 30-day mortality

    4. Association of body composition changes with nutritional support [Day 30]

      Association of changes in energy coverage and changes in body composition Association of changes in protein coverage and changes in body composition

    5. Association of muscle loss with medico-economical parameters [Day 30]

      Association of baseline muscle mass and muscle loss in the ICU with ICU and hospital costs Association of muscle loss in the ICU with level of nursing workload

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Associations of baseline body composition with clinical outcomes:

    Adults ≥ 18 yrs, hospitalized in the ICU of the HUG between January 1st 2010 and December 31st 2022 and Abdominal, or thoraco-abdominal CT scan measured 48 hours before to 96 hours after ICU admission in the HUG

    • Associations of body composition changes with clinical outcomes, nutritional support or medico-economic paratemers:

    Identical as for the associations of baseline body composition with clinical outcomes and At least one additional CT performed during the hospital stay

    Exclusion Criteria:
    • Associations of baseline body composition with clinical outcomes:

    CT scans of low quality or CT scans performed outside of the HUG or Presence of a documented refusal

    • Associations of body composition changes with clinical outcomes, nutritional support or medico-economic paratemers:

    Additionnally: oral nutrition, because we cannot assess the quantity and composition of oral intakes retrospectively

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Laurence Genton Geneva Switzerland 1211

    Sponsors and Collaborators

    • University Hospital, Geneva
    • VBertoniMaluf

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Genton Graf Laurence, Prof., University Hospital, Geneva
    ClinicalTrials.gov Identifier:
    NCT05834894
    Other Study ID Numbers:
    • 2022-01773
    First Posted:
    Apr 28, 2023
    Last Update Posted:
    Apr 28, 2023
    Last Verified:
    Apr 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Genton Graf Laurence, Prof., University Hospital, Geneva

    Study Results

    No Results Posted as of Apr 28, 2023